ACTT-1

Remdesivir for the Treatment of COVID-19

Patient / Population Intervention / Exposure Comparison Outcome

In 1,062 hospitalised COVID-19 patients, remdesivir shortened time to recovery compared with placebo.

1,062

Design

Double-blind RCT, NIAID

Endpoint

Time to recovery

Relevance

Result10 vs 15 days; 28-d mortality 11.4% vs 15.2% (HR 0.73; NS).

Beigel JH, et al. N Engl J Med. 2020;383(19):1813-1826. 10.1056/NEJMoa2007764

Discussion & critique

Faster recovery without convincing mortality signal; later WHO SOLIDARITY pooling neutral.